GleamWall
中文EN

ARQT Arcutis Biotherapeutics, Inc.

Pharmaceutical Preparations · Nasdaq · SEC CIK 1787306 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY60.0%
TTM net income YoY167.5%
TTM EPS YoY164.7%
Revenue 3-yr CAGR118.1%
Net income 3-yr CAGR—

Margins

Gross margin91.2%
Operating margin6.9%
Net margin5.9%
FCF margin11.7%
EBITDA margin—

Returns

ROE14.9%
ROA6.7%
ROIC (approx.)10.3%
Asset turnover1.14x

Leverage & solvency

Liabilities / assets53.5%
Debt / equity0.45x
Current ratio2.92x
Interest coverage2.56x

Cash quality & payout

Operating cash flow / net income2.00x
Accruals ratio-6.7%
Payout ratio—
Capex / revenue0.1%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31
Income statement
Revenue$376.07M$196.54M
Cost of revenue$36.70M$19.13M
Gross profit$339.38M$177.41M
R&D expense$77.05M$76.42M
SG&A expense$274.55M$229.39M
Operating income-$12.23M-$128.40M
Interest expense$12.08M$27.17M
Pretax income-$8.24M-$130.37M
Income tax$1.17M$647,000
Net income-$16.14M-$140.04M
EBITDA-$11.53M-$127.80M
EPS (basic)-0.13-1.16
EPS (diluted)-0.13-1.16
Weighted avg. shares (diluted)127.23M120.96M
Balance sheet
Cash & equivalents$42.91M$71.95M
Short-term investments$178.07M$156.62M
Receivables$146.23M$73.07M
Inventory$22.63M$14.53M
Current assets$411.23M$335.82M
PP&E, net$1.04M$1.04M
Intangibles$14.81M$9.48M
Total assets$432.97M$348.89M
Current liabilities$129.84M$81.01M
Short-term debt$1.00M$0
Long-term debt$107.96M$107.20M
Total debt$108.96M$107.20M
Total liabilities$243.49M$191.35M
Shareholders' equity$189.48M$157.54M
Net debt$66.05M$35.25M
Shares outstanding123.33M117.85M
Cash flow statement
Operating cash flow-$5.62M-$112.16M
Capital expenditure$686,000$143,000
Free cash flow-$6.31M-$112.30M
Investing cash flow-$30.25M$28.82M
Financing cash flow$6.97M$66.20M
Depreciation & amortization$700,000$600,000
Stock-based compensation$40.36M$41.73M

Free plan shows the latest 2 periods; Pro shows all 8 🔒

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.